

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Varadarajan Seshasayee</u>  (Last) (First) (Middle) C/O LAM RESEARCH CORPORATION 4650 CUSHING PARKWAY  (Street) FREMONT CA 94538  (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b> LAM RESEARCH CORP [ LRCX ]	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Senior Vice President
	<b>3. Date of Earliest Transaction (Month/Day/Year)</b> 03/01/2019	
<b>4. If Amendment, Date of Original Filed (Month/Day/Year)</b>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/01/2019		F		3,847	D	\$176.75	68,654 <sup>(1)</sup>	D	
Common Stock	03/01/2019		F		1,285	D	\$176.75	67,369 <sup>(1)</sup>	D	
Common Stock	03/01/2019		F		836	D	\$176.75	66,533 <sup>(1)</sup>	D	
Common Stock	03/01/2019		F		578	D	\$176.75	65,955 <sup>(1)</sup>	D	
Common Stock	03/01/2019		A		2,788 <sup>(2)</sup>	A	\$0	68,743 <sup>(1)</sup>	D	
Common Stock								224,248	I	By 401(k)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Market-based Performance Restricted Stock Unit	\$0.0	03/01/2019		A		4,647		(3)	(3)	Common Stock	4,647	\$0	4,647	D	
Employee Stock Option (Right to Buy)	\$176.75	03/01/2019		A		7,432		(4)	03/01/2026	Common Stock	7,432	\$176.75	7,432	D	

**Explanation of Responses:**

- Amount reported includes shares subject to unvested Restricted Stock Units.
- The Restricted Stock Units will vest in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022.
- These Market-based Performance Restricted Stock Units vest between 0% and 150% on 03/01/2022. The performance of this award is based on the Lam Research Total Shareholder Return performance relative to the Philadelphia Semiconductor Sector Index Total Shareholder Return during the performance period of 02/01/2019 through 01/31/2022.
- The stock option becomes exercisable in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022.

**Remarks:**

Leign Cramer by Power of  
Attorney

03/05/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Peter Ornowski, Corporate Controller, Brenna Hodgson, Sr. Finance Manager, Leign Cramer, Stock Administrator, and George Schisler, Vice President of General Legal Affairs, signing singly, to be the undersigned's true and lawful attorney-in-fact to:

(1) prepare, execute in my name and on my behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form 10, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling me to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 ("Section 16(a)") or any rule or regulation of the SEC;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Lam Research Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) and the rules thereunder;

(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of 17 May 2017.

/s/Sesha Varadarajan

Signature

Print Name: Sesha Varadarajan